Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 19, 2025
Product Development
Acquired assets deliver positive clinical data for Astrazeneca, Genmab: Clinical Report
Plus: A look at recent stock moves on clinical developments
BioCentury | Feb 20, 2025
Product Development
Solid produces best-in-class biomarker data among DMD gene therapies
BioCentury’s latest Clinical Report highlights a pair of value-driving readouts
BioCentury | Oct 25, 2024
Finance
Septerna’s GPCRs draw strong demand in $288M IPO
BioCentury’s Financial Report: ProQR’s $75M raise, Seaport’s $225M series B and more
BioCentury | Oct 4, 2024
Finance
Phase I biotechs Septerna, Orum bolster IPO queue
BioCentury’s Public Equity Report also features Caliway’s IPO, Biohaven’s $287.5M follow-on
BioCentury | Aug 26, 2024
Finance
Three’s a crowd? MBX follows Bicara, Zenas into IPO queue
Indiana-based developer of long-acting peptide therapeutics is latest mid-to-late-stage biotech to seek NASDAQ listing
BioCentury | Aug 9, 2024
Finance
Venture Report: Pair of crossover rounds for precision oncology, peptide biotechs
Plus: Financings for newcos Nilo, Jade, Red Queen
BioCentury | May 2, 2024
Data Byte
Four PDUFA dates coming in May
BMS awaits decisions on two new indications for Breyanzi; therapies from Ascendis, Dynavax also up for approvals
BioCentury | Mar 14, 2024
Deals
AstraZeneca’s Amolyt takeout among largest ever for a French biotech
Deal for $800M up front adds hypoparathyroidism asset, now in Phase III, to AZ’s Alexion portfolio; shareholders could receive $250M milestone
BioCentury | May 11, 2023
Discovery & Translation
Keeping up with the protein designers
As machine learning methods leapfrog each other, protein design companies must navigate the benefits and challenges of an ever-evolving toolbox
Items per page:
1 - 10 of 616